Important: The largest recent Phase 3 trial of thymosin alpha-1 for sepsis (TETIS, 2025) did not show a mortality benefit vs placebo. Approved-abroad status is for hepatitis indications, not anti-aging or recovery.
Overview
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5 of bovine thymic tissue by Allan Goldstein in the 1970s. It is the N-terminal fragment of prothymosin alpha, a nuclear protein involved in chromatin remodeling, and serves as a potent immunomodulatory agent that promotes T-cell maturation, enhances innate immune responses, and modulates the balance between pro- and anti-inflammatory cytokines. Tα1 is approved in over 35 countries (marketed as Zadaxin®) for the treatment of chronic hepatitis B, chronic hepatitis C, and as an adjuvant for influenza vaccination in immunocompromised patients. This extensive clinical history provides a robust human safety and efficacy dataset that distinguishes Tα1 from most research peptides.
Mechanism of Action
Thymosin Alpha-1 exerts its immunomodulatory effects through multiple mechanisms. Its primary activity involves promotion of T-cell maturation and differentiation: Tα1 stimulates the expression of T-cell surface markers (CD3, CD4, CD8) on immature thymocytes and promotes the differentiation of naive T cells toward Th1 effector phenotypes, enhancing cell-mediated immunity. Tα1 also activates toll-like receptor 9 (TLR9) signaling in dendritic cells and macrophages, stimulating the production of type I interferons (IFN-α/β) and pro-inflammatory cytokines (IL-12, TNF-α) that are critical for antiviral and antitumor immunity. Additionally, Tα1 upregulates MHC class I and II expression on antigen
Research Evidence
- Approved in 35+ countries (Zadaxin®) for hepatitis B, hepatitis C, and influenza vaccination adjuvant
- Promotes T-cell maturation and Th1 differentiation — enhances cell-mediated immunity
- TLR9 agonism in dendritic cells: stimulates type I interferon and IL-12 production
- Reverses T-cell exhaustion in chronic infection models
- Upregulates MHC class I/II on antigen-presenting cells, enhancing antigen presentation
Bottom line: Thymosin Alpha-1 is one of the most clinically validated immunomodulatory peptides in this catalog, with drug approval in over 35 countries. Its thymic origin, T-cell modulating mechanism, and clinical track record in viral infections and cancer adjuvant therapy make it a cornerstone of immune research. The research-grade lyophilized powder supplied by Purgo Labs is for laboratory use only.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Thymosin Alpha-1 are detailed in the full compound profile. See also: Dosage guide for Thymosin Alpha-1.
Sourcing & Quality
Thymosin Alpha-1 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Thymosin Alpha-1 at Purgo Labs.